AI technologies are no longer a peripheral concept in drug discovery – these platforms are a driving force for innovative companies reshaping the way we identify targets, and design, optimize, and validate novel therapeutics. Panelists will share top tips and lessons learned from crafting and negotiating significant recent transactions, from both the biotech and pharma sides of the table, with a focus on how to ensure that early transactions are structured to allow the science to drive, preserving value in the core platform technology, while maximizing the company’s growth trajectory. This panel will discuss the when, the why, and the how of partnering AI-enabled drug discovery platforms, and how an early partnering approach can drive company value and trajectory, as well as how to approach deal structuring to reflect both technological value and therapeutic potential.